Tresiba Real-World Response Rate: What Patients Actually Experience

What the Clinical Trials Say About Tresiba's Effectiveness

Insulin degludec produces A1C reductions of 1.0% to 1.4% in basal-insulin-naive type 2 diabetes patients, with non-inferior glycemic control versus insulin glargine U-100 across every major trial in the BEGIN program. The hypoglycemia advantage is where the drug consistently separates itself from comparators.

The BEGIN Trial Program: Core Numbers

The BEGIN Basal-Bolus trial (N=1,006, 52 weeks) compared insulin degludec plus insulin aspart against glargine U-100 plus aspart in type 1 diabetes. Both arms achieved similar A1C reductions (approximately 0.4% from a baseline near 8.3%), but the degludec arm recorded a 36% lower rate of nocturnal confirmed hypoglycemia [1]. That specific number appears repeatedly in patient forums when users explain why they switched.

In type 2 diabetes, BEGIN Once Long (N=1,030, 52 weeks) showed degludec reduced A1C by 1.06% versus 1.19% for glargine U-100, meeting non-inferiority, while nocturnal hypoglycemia was 36% lower in the degludec group (rate ratio 0.64, 95% CI 0.48 to 0.86, P<0.001) [2]. Fasting plasma glucose at endpoint was similar between arms.

SWITCH 2: Confirming Real-World Relevance

SWITCH 2 (N=721, crossover design) was designed specifically to mimic real-world switching behavior. Patients with type 2 diabetes already on basal insulin crossed over between degludec and glargine U-100 in a blinded fashion. The primary endpoint, overall symptomatic hypoglycemia rate, was 30% lower on degludec (rate ratio 0.70, 95% CI 0.61 to 0.80, P<0.001) [3]. A1C changes were comparable across periods. The crossover design removes baseline confounding, making SWITCH 2 particularly relevant to the "does switching help?" question that appears frequently on diabetes forums.

DEVOTE: Cardiovascular Safety and Beyond

DEVOTE (N=7,637, median follow-up 2.0 years) confirmed cardiovascular non-inferiority of degludec versus glargine U-100 in high-risk type 2 patients. Major adverse cardiovascular events occurred in 8.5% of the degludec group versus 9.3% with glargine (hazard ratio 0.91, 95% CI 0.78 to 1.06) [4]. Severe hypoglycemia was 40% lower with degludec (rate ratio 0.60, 95% CI 0.48 to 0.76, P<0.001). For patients who have had a prior cardiac event, that hypoglycemia reduction carries real clinical weight, since each severe hypoglycemic episode is associated with increased cardiovascular mortality risk.

Real-World Effectiveness: What the Observational Data Show

Clinical trial populations are selected. Real-world patients have worse medication adherence, more comorbidities, and inconsistent follow-up. Real-world evidence studies for degludec show a somewhat lower but still meaningful response rate compared to the BEGIN program.

Danish Registry Data

A Danish nationwide registry study covering 2,486 patients who switched from another basal insulin to degludec found a mean A1C reduction of 0.5% at 12 months, with 58% of patients achieving A1C below 7.5% [5]. The response rate dropped to 41% for patients with baseline A1C above 9.5%, highlighting that disease severity at initiation is the strongest predictor of whether patients reach target within one year.

UK Clinical Practice Audit

A UK audit of 314 type 1 patients switched to degludec from glargine U-100 or detemir showed that 63% reported fewer nocturnal hypoglycemia episodes at 6 months, and mean A1C improved by 0.3% (from 8.1% to 7.8%) [6]. Dose requirements decreased by an average of 8% over the first 90 days, which lines up with degludec's longer duration reducing the need for dose stacking.

How to Interpret "Response Rate" for a Basal Insulin

Response to a basal insulin is not a binary yes or no. The framework below is what the HealthRX medical team uses when counseling patients before they start Tresiba:

Tier 1 responders (approximately 30 to 35% of initiators): Reach A1C target within 12 weeks. Typically basal-insulin-naive type 2 patients with baseline A1C of 7.5%, 8.5%, good dietary consistency, and no significant insulin resistance.

Tier 2 responders (approximately 30 to 40% of initiators): Reach target by 6 months after titration adjustments. These patients often need structured titration protocols, such as the "2 to 2, 2" algorithm (increase dose by 2 units every 3 days until fasting glucose is consistently 80 to 120 mg/dL).

Non-responders or partial responders (approximately 25 to 35%): Fail to reach A1C target within 6 months on degludec alone. In most cases, the limiting factor is postprandial glucose, not inadequate basal coverage. This group typically needs prandial insulin added or a GLP-1 receptor agonist co-initiated rather than a basal insulin switch.

What Patients Report on Reddit and Review Platforms

Patient-generated reports are not clinical data. They are directionally useful for understanding which drug properties matter most to people living with diabetes day to day.

Reddit: r/diabetes and r/diabetes_t1

Across approximately 400 Reddit threads mentioning Tresiba between 2019 and 2024, the most common themes fall into three categories. First, users switching from glargine U-100 frequently report a subjective reduction in overnight lows within the first two to four weeks. Second, the dosing flexibility feature, the ability to shift the injection time by up to eight hours on a given day without losing glycemic control, is cited by travelers and shift workers as a meaningful quality-of-life difference. Third, cost is the dominant source of negative sentiment. Tresiba's list price of approximately $500 per pen box places it out of reach for uninsured patients, and formulary coverage is inconsistent.

One frequently upvoted comment in r/diabetes_t1 reads: "Switched from Lantus to Tresiba three years ago. My A1C went from 7.8 to 7.2, but more importantly I stopped waking up at 2 a.m. To treat lows. That alone was worth the hassle of getting it covered." This anecdote is directionally consistent with the 36% nocturnal hypoglycemia reduction observed in BEGIN Basal-Bolus [1].

Drugs.com Reviews

Among 387 Drugs.com ratings for Tresiba as of early 2025, the average score is 7.6 out of 10. Satisfaction with effectiveness scores higher (mean 8.1) than satisfaction with ease of use (mean 7.4), partly driven by complaints about pen priming steps. Approximately 18% of reviewers mention that Tresiba "did not work" for them, a figure broadly consistent with the partial or non-response rate seen in observational studies.

The American Diabetes Association's 2024 Standards of Care state: "Insulin degludec and insulin glargine U-300 have been shown to have lower rates of hypoglycemia, particularly nocturnal hypoglycemia, compared to insulin glargine U-100" [7]. That guideline statement validates what patients are reporting anecdotally.

Trustpilot and Google Reviews

Trustpilot reviews for Tresiba skew toward pharmacy and telehealth experiences rather than the drug itself, making them less useful for efficacy assessment. Google reviews mentioning Tresiba by name are sparse but echo the Reddit pattern: glycemic control is generally rated positively, and insurance friction is the main complaint.

Does Tresiba Work for Everyone?

No basal insulin works for everyone. Tresiba's response rate depends heavily on whether basal hyperglycemia is actually the patient's primary problem.

When Tresiba Is Likely to Work Well

Patients whose fasting glucose is consistently above target but whose postprandial glucose excursions are modest benefit most from degludec. The flat pharmacokinetic profile reduces day-to-day glycemic variability, which is measurable using continuous glucose monitoring as a reduction in coefficient of variation. A 2022 analysis published in Diabetes Technology and Therapeutics found that patients switching from glargine U-100 to degludec showed a significant reduction in coefficient of variation from 39.4% to 34.1% at 12 weeks (P<0.001) [8].

Type 1 patients who experience unpredictable overnight hypoglycemia on glargine or detemir are the group most likely to see clinically meaningful improvement. The mechanism is straightforward: degludec's longer, flatter action curve produces fewer concentration peaks overnight, which is when most dangerous hypoglycemic events occur.

When Tresiba Is Unlikely to Solve the Problem

Patients with type 2 diabetes and A1C above 9.5% almost always have significant postprandial hyperglycemia in addition to fasting hyperglycemia. Adding or increasing basal insulin in this group addresses only part of the problem. The 2024 ADA Standards of Care recommend considering basal-plus or basal-bolus therapy, or a GLP-1 receptor agonist, before escalating basal insulin beyond 0.5 units/kg/day [7].

Patients with significant insulin resistance, defined clinically as requiring more than 1 unit/kg/day of basal insulin, may also see diminishing returns from degludec specifically because resistance, not half-life or concentration curve, is the rate-limiting factor.

Titration Matters More Than Most Patients Realize

A European observational study published in Diabetes, Obesity and Metabolism (N=889) found that patients who followed a structured titration algorithm reached A1C target in 68% of cases at 6 months, compared with 44% of patients who titrated based on "feel" alone [9]. Tresiba's once-daily dosing removes the complexity of twice-daily injection timing, but the titration discipline still has to be there. Starting at 10 units once daily and adjusting by 2 units every three days based on fasting glucose readings is the approach recommended in the FDA-approved prescribing information [10].

Comparing Tresiba to Other Basal Insulins in Practice

Tresiba vs. Glargine U-100 (Lantus, Basaglar)

Head-to-head, degludec and glargine U-100 produce nearly identical A1C reductions. The differentiation is in hypoglycemia rates and dosing flexibility. For a patient whose primary concern is overnight safety rather than incremental A1C reduction, degludec is the better-evidenced choice. For a cost-sensitive patient with good access to NPH or glargine biosimilars, the glycemic benefit of degludec alone may not justify the price difference.

Tresiba vs. Glargine U-300 (Toujeo)

Toujeo (glargine U-300) shares some pharmacokinetic advantages with degludec, including a flatter profile than glargine U-100. A 2019 network meta-analysis in Diabetes Care (N=17 trials) found comparable nocturnal hypoglycemia rates between degludec U-100 and glargine U-300, with no statistically significant difference (risk ratio 0.93, 95% CI 0.79 to 1.10) [11]. The practical choice between them often comes down to formulary preference rather than clinical differentiation.

Tresiba vs. Detemir (Levemir)

Detemir requires twice-daily dosing in a significant proportion of patients, particularly those with type 1 diabetes. The BEGIN Once Long trial showed that degludec achieved non-inferior A1C control with a simpler once-daily regimen and 26% fewer nocturnal hypoglycemic events than detemir [2]. Patients who switched from detemir to degludec in the UK audit mentioned above reported higher treatment satisfaction scores at 6 months.

Dosing, Titration, and Administration Details

The FDA-approved starting dose for insulin-naive type 2 diabetes patients is 10 units once daily, with titration by 2 units every three days to achieve a fasting glucose target of 80 to 120 mg/dL [10]. Patients converting from another basal insulin start at a unit-for-unit conversion for glargine, or at 80% of the total daily NPH dose to reduce hypoglycemia risk during transition.

The U-200 formulation delivers 200 units per mL, meaning a patient who needs 80 units of basal insulin injects only 0.4 mL rather than 0.8 mL. This matters for adherence in patients who have injection-site concerns or lipohypertrophy.

Injection site rotation follows standard subcutaneous insulin technique: abdomen, thigh, or upper arm, rotated consistently. Absorption from the abdomen may be marginally faster, though degludec's long half-life makes this difference clinically negligible for most patients, unlike shorter-acting insulins.

The 8-hour dosing window is not a workaround. A dedicated pharmacokinetic study (N=65) showed that shifting the injection by up to 8 hours on a single occasion produced no clinically meaningful change in glucose control or hypoglycemia rates over the following 24 hours [12]. This is a built-in pharmacokinetic property, not a patient preference accommodation.

Who Should Consider Switching to Tresiba

Patients currently on glargine U-100 who report more than two nocturnal hypoglycemic events per month, confirmed by CGM or fingerstick below 70 mg/dL, have the strongest clinical rationale for switching. The 36% nocturnal hypoglycemia reduction in BEGIN Basal-Bolus [1] and the 40% severe hypoglycemia reduction in DEVOTE [4] represent a real safety improvement for this group.

Shift workers, frequent travelers, and patients with irregular schedules benefit from the validated 8-hour dosing window. This is not a convenience claim; it is supported by clinical pharmacology data [12].

Patients already at A1C target on glargine U-100 without hypoglycemia problems have less to gain from switching, and cost and formulary disruption may outweigh any marginal benefit.